Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | KDM5A | P29375 | 4/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14430424 | 0.89 | MEN1 (0.71) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL13979382 | 0.87 | KMT2A (0.75) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL12168832 | 0.84 | KDM5A (0.69) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL23016787 | 0.82 | KDM5A (0.69) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL23016785 | 0.82 | KDM5A (0.69) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL4007439 | 0.82 | KDM5A (0.69) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL8374162 | 0.82 | MEN1 (0.61) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL22692993 | 0.82 | CYP1A2 (0.53) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL7141667 | 0.81 | TSHR (0.58) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL18499076 | 0.81 | KMT2A (0.65) | MEN1KMT2ATSHRKDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223285-A2 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | Novartis AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-3169309-B1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS AG (CH) | 2023-05-10 | — | — | EP | disclosed |
| EP-4019506-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3083579-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2022-01-26 | — | — | EP | disclosed |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-07-13 | — | — | US | disclosed |
| WO-2016010840-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS AG (CH) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | POLN, POLRMT, RNGTT | MEN1 3053/4885KMT2A 3594/4885TSHR 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.